Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Beta Bionics, Inc. (BBNX) reported that Chief Product Officer Mike Mensinger sold 4,375 shares of common stock on September 2, 2026, in an open-market or private transaction. According to the company’s disclosure, these shares were sold to cover tax withholding obligations related to vesting restricted stock units, and Mensinger held 180,040 shares directly after the sale.
Beta Bionics, Inc. (BBNX) reported that Chief Financial Officer Stephen Feider sold 6,675 shares of common stock on September 2, 2026 at a weighted average price of $19.1131 per share, with prices ranging from $18.89 to $19.545, to cover tax withholding obligations from vesting restricted stock units, and now holds 159,378 shares directly. No Rule 10b5-1 trading plan is reported.
Beta Bionics, Inc. (BBNX) reported that President & CEO Sean Saint sold 16,867 shares of common stock on September 2, 2026 at a weighted average price of $19.1131 per share. According to the disclosure, the shares were sold to cover tax withholding obligations from vesting restricted stock units, and Saint held 404,070 shares directly after the transaction.
Beta Bionics, Inc. (BBNX) insider Mark Hopman has filed a Rule 144 notice for a proposed sale of 5,327 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an estimated aggregate value of $103,423.71 as of September 2, 2026.
The shares relate to restricted stock units vesting under a registered plan as compensation for services to Beta Bionics, and the filing describes the transaction as a sell-to-cover for taxes owed on recent vesting of stock unit awards. The notice also lists prior sales in the past three months totaling several thousand shares.
Beta Bionics, Inc. (BBNX) is the issuer for which officer Steven Jon Russell has filed a notice of proposed sale of company stock under Rule 144. The notice covers 4,221 shares of Common Stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
The shares relate to Restricted Stock Units vesting under a registered plan as compensation for services to the issuer, and the filer describes the transaction as a sell-to-cover sale to pay taxes on recently vested awards. The filing also lists a prior sale in the past three months of 4,222 shares of Common Stock.
Beta Bionics, Inc. (BBNX) is the issuer of common stock for which officer Michael R. Mensinger has filed a notice under Rule 144 to sell shares.
The notice covers 4,375 shares of common stock, with an indicated aggregate market value of $84,940.63 as of September 2, 2026, to be sold through Morgan Stanley Smith Barney LLC on Nasdaq. The shares relate to restricted stock units that vested on September 1, 2026 and are described as compensation for services rendered to Beta Bionics. Mensinger also reports that during the prior three months he sold 4,378 shares of common stock on June 2, 2026 for proceeds of $55,193.88. The filing states that the current transaction is a sell-to-cover for taxes owed on recent stock unit vesting.
Beta Bionics, Inc. (BBNX) reports that officer Stephen Feider has filed a notice under Rule 144 for a planned sale of 6,675 shares of common stock through Morgan Stanley Smith Barney LLC. The shares relate to restricted stock units that vested on September 1, 2026 as compensation for services to the issuer.
The filing states this is a sell-to-cover transaction to satisfy taxes owed on recently vested stock unit awards. In the preceding three months, Feider reported sales of 6,676, 5,104, and 4,896 shares of Beta Bionics common stock on various June 2026 dates.
Beta Bionics, Inc. (BBNX) reports that securities beneficially owned for the account of Sean Saint may be sold under Rule 144. The notice covers 16,867 shares of Common Stock, issuable from Restricted Stock Units that vested on September 1, 2026 under a registered plan, with sales to be executed through Morgan Stanley Smith Barney LLC on NASDAQ. The filing states this is a sell-to-cover transaction for taxes owed related to the recent vesting of stock unit awards. During the prior three months, a separate sale of 16,872 shares of Common Stock for $212,706.99 on June 2, 2026 is also reported.
Beta Bionics, Inc. (BBNX) received a Rule 144 notice from officer Sean Saint covering a proposed sale of common stock. The notice lists up to 5,641 shares of Beta Bionics common stock, acquired as an Equity Award on September 1, 2025, with an indicated aggregate market value of $113,258.79 and NASDAQ as the trading market.
Beta Bionics, Inc. common stock is reported as being beneficially owned by investment funds managed by Farallon Capital Management, L.L.C. and associated individuals. The reporting group collectively reports beneficial ownership of 595,000 Shares of common stock, representing 1.3% of the outstanding class as of June 30, 2026.
Farallon and its affiliated funds hold shared voting and dispositive power over these 595,000 Shares, with no sole voting or dispositive power reported for any of the listed entities or individuals. The Farallon funds are entitled to receive dividends and sale proceeds related to these securities.